[go: up one dir, main page]

MX2021005611A - Control de metales traza durante la produccion de anticuerpos anti-cd38. - Google Patents

Control de metales traza durante la produccion de anticuerpos anti-cd38.

Info

Publication number
MX2021005611A
MX2021005611A MX2021005611A MX2021005611A MX2021005611A MX 2021005611 A MX2021005611 A MX 2021005611A MX 2021005611 A MX2021005611 A MX 2021005611A MX 2021005611 A MX2021005611 A MX 2021005611A MX 2021005611 A MX2021005611 A MX 2021005611A
Authority
MX
Mexico
Prior art keywords
antibodies
during production
control
trace metals
metals during
Prior art date
Application number
MX2021005611A
Other languages
English (en)
Inventor
Nicole Larmore
Balasubramanian Ramanathan
Richard Yeager
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70551717&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2021005611(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2021005611A publication Critical patent/MX2021005611A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/01—Acid-ammonia (or amine)ligases (amide synthases)(6.3.1)
    • C12Y603/01002—Glutamate-ammonia ligase (6.3.1.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La descripción se relaciona con métodos para controlar metales traza durante la producción de anticuerpos anti-CD38, sustancias farmacológicas y productos farmacológicos generados usando los métodos, y usos de las sustancias farmacológicas y productos farmacológicos generados.
MX2021005611A 2018-11-13 2019-11-13 Control de metales traza durante la produccion de anticuerpos anti-cd38. MX2021005611A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862760782P 2018-11-13 2018-11-13
PCT/IB2019/059766 WO2020100073A1 (en) 2018-11-13 2019-11-13 Control of trace metals during production of anti-cd38 antibodies

Publications (1)

Publication Number Publication Date
MX2021005611A true MX2021005611A (es) 2021-06-30

Family

ID=70551717

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021005611A MX2021005611A (es) 2018-11-13 2019-11-13 Control de metales traza durante la produccion de anticuerpos anti-cd38.

Country Status (15)

Country Link
US (1) US11634499B2 (es)
EP (2) EP4461310A3 (es)
JP (2) JP7599418B2 (es)
KR (1) KR20210091763A (es)
CN (1) CN113015805B (es)
AU (1) AU2019379858B2 (es)
CA (1) CA3117447C (es)
EA (1) EA202191352A1 (es)
ES (1) ES2994759T3 (es)
IL (1) IL282970A (es)
MA (1) MA54248A (es)
MX (1) MX2021005611A (es)
SG (1) SG11202104092UA (es)
TW (1) TW202039849A (es)
WO (1) WO2020100073A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
CA2969717A1 (en) 2014-12-04 2016-06-09 Janssen Biotech, Inc. Anti-cd38 antibodies for treatment of acute myeloid leukemia
WO2016187546A1 (en) 2015-05-20 2016-11-24 Janssen Biotech, Inc. Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd38-positive hematological malignancies
SMT202100192T1 (it) * 2015-11-03 2021-05-07 Janssen Biotech Inc Formulazioni sottocutanee di anticorpi anti-cd38 e loro usi.
JP2019527678A (ja) 2016-06-28 2019-10-03 ユーエムセー・ユトレヒト・ホールディング・ベー・フェー ＣＤ３８に特異的に結合する抗体によるＩｇＥ媒介疾患の治療
AU2019379858B2 (en) 2018-11-13 2024-01-04 Janssen Biotech, Inc. Control of trace metals during production of anti-CD38 antibodies

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072565A (en) 1974-11-04 1978-02-07 The Dow Chemical Company Production of viruses in tissue culture without use of serum
DE3271210D1 (en) 1981-12-24 1986-06-19 Asahi Chemical Ind Method for the cultivation of normal diploid cells and cultivation medium used therefor
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
FR2543158B1 (fr) 1983-03-24 1985-11-15 Inst Nat Sante Rech Med Milieu de culture de cellules animales sans serum, sans hormones et sans facteurs de croissance et procedes de culture primaire et d'obtention de lignees cellulaires utilisant ce milieu
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US6656466B1 (en) 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
JP4306813B2 (ja) 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
US5804420A (en) 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
US6924124B1 (en) 2002-08-23 2005-08-02 Immunex Corporation Feeding strategies for cell culture
EA009383B1 (ru) 2003-03-05 2007-12-28 Хэлозим, Инк. РАСТВОРИМЫЙ ГЛИКОПРОТЕИН ГИАЛУРОНИДАЗЫ (sHASEGP), СПОСОБ ЕГО ПОЛУЧЕНИЯ, ПРИМЕНЕНИЕ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ЕГО СОДЕРЖАЩАЯ
DK1623019T4 (en) 2003-05-15 2017-03-27 Wyeth Llc LIMITED GLUCOSE SUPPLY TO ANIMAL CELL CULTURE
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
JP5225069B2 (ja) 2005-03-23 2013-07-03 ゲンマブ エー／エス 多発性骨髄腫の治療のためのｃｄ３８に対する抗体
SG10201400973XA (en) 2005-10-12 2014-08-28 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
WO2007077217A2 (en) 2006-01-04 2007-07-12 Baxter International Inc. Oligopeptide-free cell culture media
PT2495307T (pt) 2006-07-13 2018-05-10 Wyeth Llc Produção do fator ix de coagulação com padrão melhorado de glicosilação
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
US20090076249A1 (en) 2007-09-19 2009-03-19 Michel De Weers Antibodies against CD38 for treatment of multiple myeloma
CA2710373A1 (en) 2007-12-19 2009-07-09 Ping Tsui Design and generation of human de novo pix phage display libraries via fusion to pix or pvii, vectors, antibodies and methods
WO2012149197A2 (en) * 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2015011660A1 (en) * 2013-07-23 2015-01-29 Biocon Limited Methods for controlling fucosylation levels in proteins
WO2015073884A2 (en) * 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
PT3110961T (pt) * 2014-02-27 2020-01-29 Hoffmann La Roche Modulação do crescimento celular e da glicosilação na produção de glicoproteínas recombinantes
US9603927B2 (en) * 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
KR101660580B1 (ko) * 2014-04-02 2016-09-28 프레스티지 바이오파마 피티이. 엘티디. 항체의 당 함량 조절을 통한 항체의 제조 방법
US10590427B2 (en) * 2014-04-17 2020-03-17 Boehringer Ingelheim Rcv Gmbh & Co Kg Recombinant host cell for expressing proteins of interest
HUE049201T2 (hu) 2014-12-01 2020-09-28 Amgen Inc Eljárás glikoprotein glikántartalmának befolyásolására
US20160280767A1 (en) * 2015-03-23 2016-09-29 Lonza Ltd. Methods for controlling protein glycosylation
WO2016196621A1 (en) 2015-06-01 2016-12-08 Biogen Ma Inc. Manganese supplementation for control of glycosylation in mammalian cell culture process
SMT202100192T1 (it) 2015-11-03 2021-05-07 Janssen Biotech Inc Formulazioni sottocutanee di anticorpi anti-cd38 e loro usi.
AU2019379858B2 (en) 2018-11-13 2024-01-04 Janssen Biotech, Inc. Control of trace metals during production of anti-CD38 antibodies

Also Published As

Publication number Publication date
KR20210091763A (ko) 2021-07-22
WO2020100073A1 (en) 2020-05-22
EA202191352A1 (ru) 2021-08-11
JP2024129019A (ja) 2024-09-26
BR112021008879A2 (pt) 2021-10-26
JP7599418B2 (ja) 2024-12-13
JP2022513018A (ja) 2022-02-07
EP4461310A2 (en) 2024-11-13
TW202039849A (zh) 2020-11-01
EP4461310A3 (en) 2025-03-12
CN113015805B (zh) 2024-12-03
EP3880824B1 (en) 2024-07-24
EP3880824A1 (en) 2021-09-22
EP3880824A4 (en) 2022-08-10
US20200148782A1 (en) 2020-05-14
ES2994759T3 (en) 2025-01-30
CN113015805A (zh) 2021-06-22
CA3117447C (en) 2024-06-04
SG11202104092UA (en) 2021-05-28
AU2019379858B2 (en) 2024-01-04
CA3117447A1 (en) 2020-05-22
US11634499B2 (en) 2023-04-25
MA54248A (fr) 2021-09-22
IL282970A (en) 2021-06-30
AU2019379858A1 (en) 2021-05-20

Similar Documents

Publication Publication Date Title
MX2021005611A (es) Control de metales traza durante la produccion de anticuerpos anti-cd38.
PH12019502283A1 (en) Anti-lag3 antibodies
ZA202311311B (en) Anti-bcma heavy chain-only antibodies
MX2024014319A (es) Anticuerpos anti-bcma unicamente de cadena pesada
PH12020550529A1 (en) Recombinant bacterium capable of producing l-lysine, construction method thereof and production method of l-lysine
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
PH12019500540A1 (en) Anti-pd-1 antibodies and their uses
PH12019501357A1 (en) Anti-ox40 antibodies and their uses
PH12017501365A1 (en) Novel promoter and uses thereof
PH12020500576A1 (en) Method of treating cancers with antagonistic anti-pd-1 antibodies
MX2019007379A (es) Anticuerpos anti-bcma unicamente de cadena pesada.
JO3748B1 (ar) الأجسام المضادة المكافحة لـ cd38 لعلاج ابيضاض الدم النقوي الحاد
MX2021014888A (es) Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda.
EP4351045A3 (en) Methods and apparatus for setting subband csi-related parameters
MX2016016617A (es) Tratamiento de mielomas.
SG11201804488RA (en) Modifier, usage therefor, production method for modifier, and carrier for additive material
TW201612319A (en) Microorganism producing O-phosphoserine and a method for producing O-phosphoserine or L-cysteine using the same
MX391750B (es) Métodos para mejorar almenos una propiedad de un material, composiciones y usos relacionados con el mismo.
MX2018004299A (es) Metodo para la purificacion de ciclohexadec-8-en-1-ona.
FI20145305A7 (fi) Proteiinituotteet ja menetelmät niiden valmistamiseksi
EP4480577A3 (en) Structured elements and methods of use
MX2022002563A (es) Nuevo promotor y metodo para producir la sustancia deseada usando el mismo.
MY174840A (en) Microorganism producing o-acetyl-homoserine, and method for producing o-acetyl-homoserine by using same
MX2019009136A (es) Aparato y proceso de flujo continuo para la produccion de derivado de acido boronico.
WO2018093154A3 (ko) 카이스티아 속 미생물을 이용한 d-사이코스 제조방법